The Idiopathic Pulmonary Fibrosis Management Market Size is valued at USD 3,113.5 Mn in 2023 and is predicted to reach USD 3,429.6 Mn by the year 2031 at a 1.28% CAGR during the forecast period for 2024-2031.
Idiopathic Pulmonary Fibrosis Management is referred to as a serious disease related to the lungs, which stiffens, thickens, and damages the lung tissues over a prolonged period. Hence, the adoption of idiopathic pulmonary fibrosis management is expected to increase in the near future as concerns grow over people's health. The growing prevalence of Idiopathic Pulmonary Fibrosis in middle-aged men is a factor expected to drive the development of the global Idiopathic Pulmonary Fibrosis Management market. The availability of several treatments and the adoption of newly advanced technology are some of the other factors estimated to augment the target market growth. The rapid advancements in research and drug innovations globally are expected to push the market expansion in the coming years.
However, The high cost of Idiopathic Pulmonary Fibrosis Management, lack of treatment, and COVID-19 outbreak may hinder target market expansion over the forecast period. Enhanced R&D, government initiatives promoting sustainable production components, and investments from leading entities are expected to generate significant revenue growth opportunities for global Idiopathic Pulmonary Fibrosis Management market participants during the forecast period.
The Idiopathic Pulmonary Fibrosis Management market is segmented based on drug class, route of administration, and distribution channel. The drug class segment comprises pirfenidone, nintedanib, interferon gammato1b, and others. According to the route of administration, the segmention includes oral, injectable, and others. The distribution channel segment includes hospital pharmacies, retail pharmacies, and others.
The pirfenidone category is expected to hold a major share of the global Idiopathic Pulmonary Fibrosis Management market in 2023. This is attributed to providing a unique combination of anti-fibrotic, antioxidant, and anti-inflammatory properties. Additionally, its efficiency is proven in clinical trials and continuous research and development initiatives, which are rapidly raising its value and attractiveness to the healthcare sector.
The hospital pharmacies projected to grow at a rapid rate in the global Idiopathic Pulmonary Fibrosis Management market owing to its advanced diagnostic tools. Additionally, hospital pharmacies offer expert guidance on medication use and administration, ensuring optimal patient care in the rising prevalence of Idiopathic Pulmonary Fibrosis Management in hospital pharmacies.
The North American idiopathic Pulmonary Fibrosis Management market is expected to register the highest market revenue share in the comming future. This can be attributed to the strong focus on lung patients in the region, with the increasing adoption of Idiopathic Pulmonary Fibrosis Management. In addition, the advanced properties in healthcare infrastructure, specialized IPF diagnosis, well-equipped infrastructure, and providing timely and effective treatment. Growing research and development, as well as improved access to approved therapies for idiopathic pulmonary fibrosis management in the production of intermediate chemicals in the region, are factors increase the growth of the target market in the region. Also, Asia Pacific region is projected to show rapid growth in the global Idiopathic Pulmonary Fibrosis Management market due to growing pharmaceutical innovations, rising demand for effective treatment, rapid industrialization, government initiatives, and increasing funding in various industries.
|
Report Attribute |
Specifications |
|
Market Size Value In 2023 |
USD 3,113.5 Mn |
|
Revenue Forecast In 2031 |
USD 3,429.6 Mn |
|
Growth Rate CAGR |
CAGR of 1.28% from 2024 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Mn and CAGR from 2024 to 2031 |
|
Historic Year |
2019 to 2023 |
|
Forecast Year |
2024-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Drug Class, Treatment, Route Of Administration, And Distribution Channel |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South East Asia; South Korea |
|
Competitive Landscape |
Avalyn Pharma, Inc., F. Hoffmann-La Roche Ltd, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Medicinova, Inc., Merck & Co., Inc., Galapagos NV, Novartis AG, Fiberogen, Inc., Biogen, Blade Therapeutics, Neopharm Group, Galecto Biotech, Pfizer Inc, Johnson & Johnson Services, Inc., AstraZeneca, Daewoong Pharmaceutical (India) Pvt Ltd, Sandoz International GmbH (Novartis), Algernon Pharmaceuticals Inc., and Genentech, Inc. |
|
Customization Scope |
Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Idiopathic Pulmonary Fibrosis Management Market Snapshot
Chapter 4. Global Idiopathic Pulmonary Fibrosis Management Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Porter's Five Forces Analysis
4.7. Incremental Opportunity Analysis (US$ MN), 2024-2031
4.8. Global Idiopathic Pulmonary Fibrosis Management Market Penetration & Growth Prospect Mapping (US$ Mn), 2023-2031
4.9. Competitive Landscape & Market Share Analysis, By Key Player (2023)
4.10. Use/impact of AI on Idiopathic Pulmonary Fibrosis Management Industry Trends
Chapter 5. Idiopathic Pulmonary Fibrosis Management Market Segmentation 1: By Drug Class, Estimates & Trend Analysis
5.1. Market Share by Drug Class, 2023 & 2031
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following Drug Class:
5.2.1. Pirfenidone
5.2.2. Nintedanib
5.2.3. Interferon Gammato1b
5.2.4. Others
Chapter 6. Idiopathic Pulmonary Fibrosis Management Market Segmentation 2: By Treatment, Estimates & Trend Analysis
6.1. Market Share by Treatment, 2023 & 2031
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following Treatments:
6.2.1. Oxygen Therapy
6.2.2. Lung Transplant
6.2.3. Others
Chapter 7. Idiopathic Pulmonary Fibrosis Management Market Segmentation 3: By Route of Administration, Estimates & Trend Analysis
7.1. Market Share by Route of Administration, 2023 & 2031
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following Route of Administration:
7.2.1. Oral
7.2.2. Injectable
Chapter 8. Idiopathic Pulmonary Fibrosis Management Market Segmentation 4: By Distribution Channel, Estimates & Trend Analysis
8.1. Market Share by Distribution Channel, 2023 & 2031
8.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following Distribution Channel:
8.2.1. Hospital Pharmacies
8.2.2. Retail Pharmacies
8.2.3. Online Pharmacies
Chapter 9. Idiopathic Pulmonary Fibrosis Management Market Segmentation 5: Regional Estimates & Trend Analysis
9.1. Global Idiopathic Pulmonary Fibrosis Management Market, Regional Snapshot 2023 & 2031
9.2. North America
9.2.1. North America Idiopathic Pulmonary Fibrosis Management Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2031
9.2.1.1. US
9.2.1.2. Canada
9.2.2. North America Idiopathic Pulmonary Fibrosis Management Market Revenue (US$ Million) Estimates and Forecasts by Drug Class, 2024-2031
9.2.3. North America Idiopathic Pulmonary Fibrosis Management Market Revenue (US$ Million) Estimates and Forecasts by Treatment, 2024-2031
9.2.4. North America Idiopathic Pulmonary Fibrosis Management Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2024-2031
9.2.5. North America Idiopathic Pulmonary Fibrosis Management Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2024-2031
9.3. Europe
9.3.1. Europe Idiopathic Pulmonary Fibrosis Management Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2031
9.3.1.1. Germany
9.3.1.2. U.K.
9.3.1.3. France
9.3.1.4. Italy
9.3.1.5. Spain
9.3.1.6. Rest of Europe
9.3.2. Europe Idiopathic Pulmonary Fibrosis Management Market Revenue (US$ Million) Estimates and Forecasts by Drug Class, 2024-2031
9.3.3. Europe Idiopathic Pulmonary Fibrosis Management Market Revenue (US$ Million) Estimates and Forecasts by Treatment, 2024-2031
9.3.4. Europe Idiopathic Pulmonary Fibrosis Management Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2024-2031
9.3.5. Europe Idiopathic Pulmonary Fibrosis Management Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2024-2031
9.4. Asia Pacific
9.4.1. Asia Pacific Idiopathic Pulmonary Fibrosis Management Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2031
9.4.1.1. India
9.4.1.2. China
9.4.1.3. Japan
9.4.1.4. Australia
9.4.1.5. South Korea
9.4.1.6. Hong Kong
9.4.1.7. Southeast Asia
9.4.1.8. Rest of Asia Pacific
9.4.2. Asia Pacific Idiopathic Pulmonary Fibrosis Management Market Revenue (US$ Million) Estimates and Forecasts by Drug Class, 2024-2031
9.4.3. Asia Pacific Idiopathic Pulmonary Fibrosis Management Market Revenue (US$ Million) Estimates and Forecasts by Treatment, 2024-2031
9.4.4. Asia Pacific Idiopathic Pulmonary Fibrosis Management Market Revenue (US$ Million) Estimates and Forecasts By Route of Administration, 2024-2031
9.4.5. Asia Pacific Idiopathic Pulmonary Fibrosis Management Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2024-2031
9.5. Latin America
9.5.1. Latin America Idiopathic Pulmonary Fibrosis Management Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2031
9.5.1.1. Brazil
9.5.1.2. Mexico
9.5.1.3. Rest of Latin America
9.5.2. Latin America Idiopathic Pulmonary Fibrosis Management Market Revenue (US$ Million) Estimates and Forecasts by Drug Class, 2024-2031
9.5.3. Latin America Idiopathic Pulmonary Fibrosis Management Market Revenue (US$ Million) Estimates and Forecasts by Treatment, 2024-2031
9.5.4. Latin America Idiopathic Pulmonary Fibrosis Management Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2024-2031
9.5.5. Latin America Idiopathic Pulmonary Fibrosis Management Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2024-2031
9.6. Middle East & Africa
9.6.1. Middle East & Africa Idiopathic Pulmonary Fibrosis Management Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031
9.6.1.1. GCC Countries
9.6.1.2. Israel
9.6.1.3. South Africa
9.6.1.4. Rest of Middle East and Africa
9.6.2. Middle East & Africa Idiopathic Pulmonary Fibrosis Management Market Revenue (US$ Million) Estimates and Forecasts by Drug Class, 2024-2031
9.6.3. Middle East & Africa Idiopathic Pulmonary Fibrosis Management Market Revenue (US$ Million) Estimates and Forecasts by Treatment, 2024-2031
9.6.4. Middle East & Africa Idiopathic Pulmonary Fibrosis Management Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2024-2031
9.6.5. Middle East & Africa Idiopathic Pulmonary Fibrosis Management Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2024-2031
Chapter 10. Competitive Landscape
10.1. Major Mergers and Acquisitions/Strategic Alliances
10.2. Company Profiles
10.2.1. Boehringer Ingelheim GMBH
10.2.1.1. Business Overview
10.2.1.2. Key Product/Service Offerings
10.2.1.3. Financial Performance
10.2.1.4. Geographical Presence
10.2.1.5. Recent Developments with Business Strategy
10.2.2. Biogen
10.2.3. Novartis AG
10.2.4. Medicinova Inc
10.2.5. Bristol Myers Squibb Company
10.2.6. Galapagos NV
10.2.7. Hoffmann-La Roche AG
10.2.8. Neopharm Group
10.2.9. Galecto Biotech
10.2.10. Pfizer Inc
10.2.11. Johnson & Johnson Services, Inc
10.2.12. AstraZeneca
10.2.13. Other Prominent Players
Idiopathic Pulmonary Fibrosis Management Market By Product-
Idiopathic Pulmonary Fibrosis Management Market By Route of Administration-
Idiopathic Pulmonary Fibrosis Management Market By Treatment-
Idiopathic Pulmonary Fibrosis Management Market By Distribution Channel-
By Region-
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-
InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.
Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.
Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.
Secondary research
The secondary research sources that are typically mentioned to include, but are not limited to:
The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista
Primary Research:
Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies
The contributors who typically take part in such a course include, but are not limited to:
Data Modeling and Analysis:
In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.
The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.
